Oncology · 1 h ago
Divarasib Improves Survival in Phase III Trial of KRAS G12C-Mutated NSCLC
A global, randomized Phase III trial involving 338 adults with previously treated KRAS G12C-mutated NSCLC compared investigational divarasib with sotorasib or adagrasib. A company-sponsored press release reports longer overall and progression-free survival with divarasib; the drug is not approved.
- 338 patients were randomly assigned in Phase III Krascendo 1.
- Median overall survival was 17.7 versus 12.0 months.
- Divarasib remains investigational and is not approved.
The global Phase III Krascendo 1 trial randomly assigned 338 adults with previously treated, locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer to investigational divarasib or one of the approved KRAS G12C inhibitors sotorasib and adagrasib. Tennessee Oncology investigators participated. The trial was sponsored by Genentech, part of the Roche Group; results were presented at the 2026 ESMO Congress and published in The New England Journal of Medicine, according to the release.
The release reports a 42% lower risk of disease progression or death and a 44% lower risk of death with divarasib versus the first-generation inhibitors. Median overall survival was 17.7 months versus 12.0 months. It also reports longer progression-free survival and nearly twice the objective response rate, but provides no confidence intervals, event counts, or detailed safety results.
The findings suggest potential benefit from a next-generation KRAS G12C inhibitor in this previously treated population. Divarasib remains investigational and has not been approved by the FDA or another regulatory authority. The source is a Tennessee Oncology press release describing sponsor-funded trial findings; clinical interpretation should rely on the full peer-reviewed report, including safety and efficacy details.
In practice
For adults with previously treated, locally advanced or metastatic KRAS G12C-mutated NSCLC, the randomized Phase III Krascendo 1 results reported longer overall survival with divarasib than with sotorasib or adagrasib. This is promising comparative evidence, but divarasib remains investigational and the source does not provide confidence intervals, detailed safety findings, or other information needed to assess the results fully. The release alone does not support changing treatment practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
PR Newswire – Health: Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.